Overview

Hypersensitivity to Opening of BKCa Channels in Post-Traumatic Headache

Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
0
Participant gender:
All
Summary
The aim is to investigate whether opening of large conductance calcium-activated potassium (BKCa) channels induces headache with migraine-like features in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Danish Headache Center
Criteria
Inclusion Criteria:

Age 18 to 65 years of age upon entry into screening History of persistent headache
attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the
International Classification of Headache Disorders, 3rd Edition (ICHD-3)

≥ 4 monthly headache days on average across the 3 months prior to screening Provision of
informed consent prior to initiation of any study-specific activities/procedures.

Exclusion Criteria:

> 1 mild traumatic injury to the head History of any primary or secondary headache disorder
prior to mild traumatic injury to the head (except for infrequent episodic tension-type
headache) History of moderate or severe injury to the head History of whiplash injury
History of craniotomy History or evidence of any other clinically significant disorder,
condition or disease (except for those outlined above) than, in the opinion of the site
investigator, would pose a risk to subject safety or interfere with study evaluation,
procedures or completion The subject is at risk of self-harm or harm to others as evidenced
by past suicidal behavior Female subjects of childbearing potential with a positive
pregnancy test during any study visit Cardiovascular disease of any kind, including
cerebrovascular diseases Hypertension (systolic blood pressure of ≥150 mmHg and/or
diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental
day Hypotension (systolic blood pressure of ≤90 mmHg and/or diastolic blood pressure of ≤50
mmHg) Initiation, discontinuation, or change of dosing of prophylactic medications within 2
months prior to study inclusion Intake of acute medications (e.g. analgesics, triptans)
within 48 hours of infusion start Baseline headache intensity of >3 on an 11-point numeric
rating scale (0 being no headache, 10 being the worst imaginable headache) Baseline
headache with migraine-like features or self-reported baseline headache that mimics the
subjects' usual headache with migraine-like features